GlobeNewswire Medical EquipmentDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:01:55·⚡ 决策 10-22 20:03:48 +1m53s·5.3 天前
Senseonics 宣布管理层将于11月参加两场投资者会议，属例行IR日程无新增经营信息
这是一份典型的IR日程公关稿：仅告知管理层将在近三周后参加两场常规行业投资者会议并提供webcast，未披露任何业绩、指引、新产品、订单或合作信息。会议本身(11月10-11日)尚未发生，今天无任何surprise，不构成方向性催化；小盘CGM股的会议路演也不具备可在公告日交易的正期望edge。
📄 原文GlobeNewswire Medical Equipment↗ 原文
Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology compa…
不做 Senseonics Holdings, Inc.（SENS.US）
例行投资者会议参会公告，无任何经营/财务/产品新增事实，会议11月10-11日才召开，公告日无方向性催化与正期望edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Senseonics公告管理层11月参加Stifel和Canaccord两场投资者会议，属例行IR日程、无新增经营或财务事实，会议尚未召开，不构成可交易事件，回避。
🔎 新鲜度:最早出现 2026-10-22 · 扩散 low · price-in 风险 low ↗
主要风险
- 会议当天(11月10-11日)管理层若在演示或一对一会议中释放产品/业绩新信息可能引发波动，但那是未来事件、本公告不含该信息。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-22 · 影响 none
公告本身及日程信息中没有任何新增利好或利空事实；做多缺乏基本面催化，无需进一步反证。
检索:Senseonics SENS conference announcement guidance product news 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认不交易：不引用任何涨幅基准，直接AVOID。
方向:无先例统计需求：例行参会公告属非催化型公司行动，历史上此类IR日程稿通常不产生事件日超额收益，公告本身不提供方向性edge。
涨幅量级:不足以也无必要校准幅度——没有可交易的事件级surprise。
形态:常规会议参会公告一般无事件日系统性反应，真正波动多发生在会议当天有实质披露时，而非日程公告日。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,954 ms
{"result": "search_processed_events:agent query=`sens management fireside chat one-on-one meetings conference 2026 | senseonics holdings investor conferences november stifel canaccord genuity`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26078 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复
原文全文
展开原文 · 1,705 字
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November:
Stifel 2026 Healthcare Conference – November 10-12, 2026 (New York, NY)
Management will participate in a fireside chat at 3:20 pm ET and host one-on-one meetings with investors on Tuesday, November 10
th
.
Click here
to access the live webcast.
20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health Forum – November 11, 2026 (New York, NY)
Management will present at 10:30 am ET and will host one-on-one meetings with investors on Wednesday, November 11
t
h
.
Click here
to access the live webcast.
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at
www.senseonics.com
.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense
®
365 and Eversense
®
E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
Stifel 2026 Healthcare Conference – November 10-12, 2026 (New York, NY)
Management will participate in a fireside chat at 3:20 pm ET and host one-on-one meetings with investors on Tuesday, November 10
th
.
Click here
to access the live webcast.
20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health Forum – November 11, 2026 (New York, NY)
Management will present at 10:30 am ET and will host one-on-one meetings with investors on Wednesday, November 11
t
h
.
Click here
to access the live webcast.
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at
www.senseonics.com
.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense
®
365 and Eversense
®
E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
3e796822e4· 2026-10-22 20:03 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前